Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials
about
Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosisM1 and M2 immune activation in Parkinson's Disease: Foe and ally?Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesInterleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritisAn efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.Detection of biomarkers using recombinant antibodies coupled to nanostructured platformsPhage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritisComparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.The immunological contribution to heterotopic ossification disorders.Adalimumab in the therapy of uveitis in childhoodReview of health economics modelling in rheumatoid arthritis.Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.Current imaging strategies in rheumatoid arthritisChange in physiotherapy management of children with cystic fibrosis in a large urban hospital.Treating psoriasis with adalimumab.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.Biological therapies for rheumatoid arthritis: progress to date.Biological therapies for psoriasis.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.The maturation of antibody technology for the HIV epidemic.Monoclonal antibodies: technologies for early discovery and engineering.Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Developing anti-inflammatory therapeutics for patients with osteoarthritis.Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.An extraordinary form of the Melkersson-Rosenthal syndrome successfully treated with the tumour necrosis factor-α blocker adalimumab.Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency.Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab.Anti tumor necrosis factor - alpha adalimumab for complex regional pain syndrome type 1 (CRPS-I): a case series.Synthesis and biological evaluation of imidazo[1,2-[Formula: see text]]pyridazines as inhibitors of TNF-[Formula: see text] production.Therapeutics in Osteoarthritis Based on an Understanding of Its Molecular Pathogenesis.Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
P2860
Q27013600-0D90FFAA-F65D-4D31-A59E-514B81090D90Q27024667-1F5D7DD6-4AF5-4852-ADBA-29D716ECA33EQ30240229-3BD60AEE-3787-4E7E-A758-92F4F32300FCQ33629320-43C5AA95-AC36-4CC0-B12B-E32859F1FB06Q34047753-8615DF39-7F74-44EF-8E7B-C0B32F8CA963Q34248283-009F2D0A-4405-41AB-87F4-1F810169C64DQ34301659-372F0F1A-74A1-437D-B350-6A5E76BCD193Q34352221-0CD3670D-1472-42F5-9975-0696D2D647F3Q34385892-2985172D-F5AE-40E3-A4C4-BBC7C216B082Q35553042-3C9057C8-AAB3-4F4C-A17D-D810BD717D06Q35553459-2CE7C44F-8F45-4C4F-B13F-182B26322388Q35563973-D47FBA0D-FE51-4996-AFF0-5A5ABDE8DD4AQ35763157-768ABB76-3BAD-44DD-B51E-415ACD696D8CQ35780357-AA5121A8-DB0C-4710-8887-52F4313460A5Q35973747-DF6380F3-AD6B-4DDE-99EA-EABCF8133446Q36300479-5A7D55B7-DA93-4F48-B470-99905897098AQ36337258-CB31CA05-ED96-416A-AAE0-0673A401B440Q36356947-E332C156-934A-4067-9435-24E4DB5C479BQ36823592-03CE38D4-13A2-4FF6-9CA9-51FEE87F2DD6Q37453905-778EB259-C03E-4495-A6B2-9782C5F3A9DEQ37728019-0A349B91-BE54-42D9-9A19-74CADBDFC8D0Q38096206-6E188FB1-41B8-4187-B24E-EDDCC0A075FBQ38155648-D3C9B4B4-95A3-4C03-B607-29B230188905Q38207759-CA3D96C3-5A3A-4885-99BB-551DD03D2171Q38209477-BFF7B451-3F81-421C-B8E2-748C5D04ED38Q38633596-FEDFCE74-1A2E-492C-B600-EE100F5C4C18Q38643965-D3CFD737-6FB2-4A0A-8CF1-91DA50C59DE2Q38645738-471EBA0E-6781-41E7-ADBF-04C110334E05Q38833741-8C30DE22-4AD1-47ED-835E-44DCD827C940Q39392775-41ACE323-3218-4205-98D2-B6CF202D8494Q39701850-74617C7B-959B-47E3-8FA0-DB379C9724A7Q44995645-B0E43EEB-8423-4D70-9498-AEDEDEAF72BEQ45854900-C3786B42-9248-47E1-88C1-4BEC2193B97CQ48475627-DB84BDD5-554F-40F1-B56D-88B179C6E112Q48500215-8E10CD2C-989B-440D-8838-01D2A90017EAQ52679053-2F338E4D-2F4F-426C-9363-43BA3816E293Q53572128-23A5B7D5-3482-4086-B18D-003BC32E6119Q58782953-2469D469-9890-4E7C-972D-6B45B6260CBF
P2860
Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Adalimumab (a fully human anti ...... initial results of five trials
@ast
Adalimumab (a fully human anti ...... initial results of five trials
@en
Adalimumab (a fully human anti ...... initial results of five trials
@nl
type
label
Adalimumab (a fully human anti ...... initial results of five trials
@ast
Adalimumab (a fully human anti ...... initial results of five trials
@en
Adalimumab (a fully human anti ...... initial results of five trials
@nl
prefLabel
Adalimumab (a fully human anti ...... initial results of five trials
@ast
Adalimumab (a fully human anti ...... initial results of five trials
@en
Adalimumab (a fully human anti ...... initial results of five trials
@nl
P2860
P921
P1476
Adalimumab (a fully human anti ...... initial results of five trials
@en
P2093
P2860
P304
P356
10.1136/ARD.61.SUPPL_2.II70
P407
P433
Supplement 2
P478
61 Suppl 2
P577
2002-11-01T00:00:00Z